

24 **Abstract**

25 The aim of this study was to examine the association of insulin resistance (evaluated by the short
26 insulin tolerance test [SITT]) with parameters related to obesity and insulin resistance. We prospectively
27 recruited controls and patients with type 2 diabetes mellitus (T2DM), subjected them to the SITT, and
28 calculated the K indices of the intravenous insulin tolerance test ($K_{ITT(iv)}$) and the subcutaneous insulin
29 tolerance test ($K_{ITT(sc)}$). We compared $K_{ITT(iv)}$ between the volunteers and patients, and examined its
30 correlation with $K_{ITT(sc)}$. We also examined the association of $K_{ITT(iv)}$ with obesity, insulin resistance-
31 related parameters, and the insulin dose required for glycemic control. A total of 24 participants (seven
32 controls and 17 patients with T2DM) were studied. The mean $K_{ITT(iv)}$ was significantly lower in patients
33 with T2DM than in the controls ($2.5\% \pm 2.1\%$ vs. $4.5\% \pm 1.8\%$). In all participants, $K_{ITT(iv)}$ was significantly
34 correlated with the HOMA-IR values ($r = -0.601$, $p < 0.05$) but not with $K_{ITT(sc)}$ ($p = 0.62$). $K_{ITT(iv)}$ was
35 correlated positively with the serum adiponectin concentration, but negatively with the visceral fat area and
36 serum concentrations of tumor necrosis factor- α and branched-chain amino acids. In patients with T2DM,
37 $K_{ITT(iv)}$ and HOMA-IR values were significantly correlated with the total insulin dose required for
38 glycemic control. Insulin resistance evaluated using intravenous insulin ($K_{ITT(iv)}$) was correlated with the
39 HOMA-IR values, but not with the resistance evaluated using subcutaneous insulin ($K_{ITT(sc)}$). The degree
40 of insulin resistance was associated with biomarkers, such as adiponectin, and with the dose of insulin
41 required for glycemic control.

42

43

44 Introduction

45 Insulin resistance is a cardinal feature of the pathogenesis of non-insulin-dependent diabetes mellitus
46 [1]. Precise estimation of insulin resistance is important to understand the mechanism underlying the
47 impairment of glycemic control and accordingly optimize the treatment for patients with diabetes.

48 The hyperinsulinemic euglycemic glucose clamp test (HEGCT) is the gold standard for evaluating
49 insulin resistance [2]. However, it is complicated and difficult to perform in many patients. The
50 homeostasis model assessment for insulin resistance (HOMA-IR value) is another test that is frequently
51 used for evaluating the insulin resistance. HOMA-IR can be performed readily and is well correlated with
52 the HEGCT [3]. However, in patients with diabetes mellitus with high fasting plasma glucose (FPG)
53 levels (who may have a decreased insulin secretion), it is less accurate as an indicator of insulin resistance
54 [4]. In addition, HOMA-IR cannot estimate insulin resistance in patients with diabetes who are receiving
55 insulin therapy [4].

56 The short insulin tolerance test (SITT) is a simple and convenient method for estimating insulin
57 resistance [5, 6]. In the SITT, regular insulin is administered intravenously, and blood samples are
58 collected sequentially for 15 min; the plasma glucose disappearance rate is then estimated [5, 6]. The K
59 index of the insulin tolerance test (K_{ITT}) is calculated from the linear slope of the plasma glucose
60 concentration curve and correlates well with the HEGCT [3, 7]. The SITT can assess whole-body insulin
61 sensitivity even in patients with decreased insulin secretion or on insulin therapy. However, the SITT
62 carries a risk of hypoglycemia [5, 8], and K_{ITT} estimation requires multiple blood sampling. Theoretically,
63 K_{ITT} can be estimated more easily by administering insulin subcutaneously without venous blood
64 sampling, e.g., finger pricking, and using the glucose concentration in finger-prick blood. Furthermore,
65 rapid hypoglycemia is less likely to occur with subcutaneous insulin administration than with intravenous
66 insulin administration. However, the accuracy of K_{ITT} has not been validated.

67 Previous studies have provided the K_{ITT} values from intravenous SITT ($K_{ITT}(iv)$) in humans [3, 5, 6,
68 7, 9]. Especially in patients with poorly controlled diabetes mellitus, $K_{ITT}(iv)$ is considered more accurate
69 than HOMA-IR because it is not affected by a decreased insulin secretory capacity. However, few studies
70 [10] have examined the association between $K_{ITT}(iv)$ and other parameters related to obesity and insulin
71 resistance (such as visceral fat, adiponectin, and tumor necrosis factor [TNF]- α). Such data will improve
72 the understanding of the pathogenesis of insulin resistance and help optimize the treatment in each
73 patient. Furthermore, the application of $K_{ITT}(iv)$ for predicting the amount of insulin required would be
74 useful in practice.

75 In the present prospective study, we calculated $K_{ITT}(iv)$ in healthy volunteers and patients with type 2
76 diabetes mellitus (T2DM). Using $K_{ITT}(iv)$ as a reference, we then evaluated the accuracy of HOMA-IR
77 and the K_{ITT} obtained using glucose concentration of fingertip blood (i.e., after subcutaneous insulin
78 injection [$K_{ITT}(sc)$]). We also investigated the relationship between $K_{ITT}(iv)$ and the parameters related

79 to obesity and insulin resistance, and examined the possible role of $K_{ITT(iv)}$ in predicting the insulin dose
80 required for glycemic control in patients with T2DM.

81

82 **Methods**

83 **Study participants**

84 This was a single-center, randomized, crossover study with 17 patients with T2DM (who were
85 admitted to the Hokkaido University Hospital for glycemic control) and seven healthy volunteers
86 (controls). The registration period was from November 2016 to July 2019.

87 The inclusion criteria for the controls were as follows: age ≥ 30 years; body mass index, >18.5
88 kg/m^2 ; and no previous diagnosis of diabetes or impaired glucose tolerance. The inclusion criteria for the
89 patients were as follows: age ≥ 20 years, T2DM diagnosis based on the American Diabetes Association
90 Criteria [11], and FPG level ≥ 140 mg/dL during hospitalization. The exclusion criteria for the controls
91 were as follows: history of hypoglycemia (blood glucose < 60 mg/dL), untreated ischemic heart disease,
92 epilepsy, pregnancy, possible pregnancy, lactation, and researcher-determined ineligibility. The exclusion
93 criteria for the patients were as follows: unstable diabetic retinopathy, stage ≥ 4 diabetic nephropathy,
94 untreated ischemic heart disease, history of hypersensitivity to human regular insulin, epilepsy,
95 pregnancy, possible pregnancy, lactation, and deemed ineligible by the researcher.

96

97 **Crossover assignment to the insulin tolerance test with**

98 **intravenous or subcutaneous insulin**

99 After case enrollment using the central registration system by the research persons, the
100 participants were assigned to undergo either of the following pathways: 1) the SITT first (with
101 intravenous insulin injection), followed by an insulin tolerance test with subcutaneous insulin injection
102 (ITTsc) or 2) the ITTsc first, followed by the SITT. This assigning of the patients was performed on a 1:1
103 basis by the research office, and the results were communicated to the co-investigators in writing. The
104 two insulin tolerance tests (SITT and ITTsc) were completed within 3 days, irrespective of the order(Fig
105 1).

106

107 **Pre-test preparations**

108 The controls arrived at the hospital in the morning after fasting overnight to participate in the
109 study. Patients with T2DM, after admission to the hospital, were started on a diet (25–30 kcal/kg standard

110 body weight/day); metformin, pioglitazone, and sodium glucose transporter 2 inhibitors were withdrawn
111 on admission. The patients' fasting venous blood was collected the day after admission; if the FPG level
112 was >140 mg/dL, the patient was included in this study. The controls and patients both underwent the
113 SITT and ITTsc after overnight fasting.

114

115 **SITT procedures**

116 The SITT was performed before breakfast. Venous blood samples were collected for
117 measurement of plasma glucose before and at 3, 6, 9, 12, and 15 min after an intravenous bolus injection
118 of regular human insulin (0.1 U/kg bodyweight; Eli Lilly®, Eli Lilly and Company, IN, USA). Fifteen
119 minutes after the insulin injection, the test was completed by injecting 20 mL of 50% glucose solution.
120 K_{ITT} [now labelled $K_{ITT(iv)}$] was calculated from the linear slope of the curve of plasma glucose
121 concentrations at the 3–15-min timepoints using the Lundbaek equation [12].

122

123 **ITTsc procedures**

124 The ITTsc was performed before breakfast. Finger-prick blood samples were collected for the
125 measurement of blood glucose before, and at 3, 6, 9, 12, 15, 30, 45, 60, 75, 90, and 120 min after a
126 subcutaneous injection of regular human insulin (0.1 U/kg bodyweight). The K_{ITT} (now labelled $K_{ITT(sc)}$)
127 was calculated from the linear slope of the curve of finger-pick blood glucose concentrations at the 30-
128 120 min timepoints using the Lundbaek equation.

129

130 **Clinical parameters related to insulin resistance**

131 The waist circumference and waist-to-hip ratio before breakfast were measured during the first
132 ITT. The visceral fat area (VFA) was calculated using the bioimpedance method (BIM; InBody770®,
133 InBody Japan Inc., Tokyo, Japan). We measured the fasting serum C-peptide immunoreactivity (CPR);
134 levels of fasting immunoreactive insulin (F-IRI), adiponectin, leptin, and TNF- α ; and concentrations of
135 plasma amino acids (AA) and branched chain AAs (BCAA) using the baseline (0 min) blood sample from
136 the SITT or ITTsc (whichever was performed first). The HOMA-IR values were calculated using the
137 following formula: $HOMA-IR = (FPG [mg/dL] \times F-IRI [\mu U/mL])/405$. F-IRI and the HOMA-IR values
138 were not determined in insulin-treated patients.

139

140 **Insulin treatment after SITT/ITTsc**

141 After the SITT and ITTsc, all 17 patients with T2DM were treated with multiple daily insulin

142 injections. Basal and bolus insulin doses were adjusted until the FPG levels were ≤ 130 mg/dL and the
143 postprandial plasma glucose levels were ≤ 180 mg/dL. The total insulin dose used for glycemic control
144 was then calculated. Using $K_{ITT(iv)}$ and the HOMA-IR value, equations by which the total insulin dose
145 (/body weight) could be calculated were formed.
146

147 **Statistical analyses**

148 Data are expressed as mean \pm standard deviation. The required sample size was determined to
149 be 19 after assuming a correlation coefficient of 0.6 between $K_{ITT(iv)}$ and $K_{ITT(sc)}$, a power of 80%, and a
150 significance level of 5%. However, the actual sample size was set at 24, assuming a 20% dropout rate.

151 We compared $K_{ITT(iv)}$ between the controls and patients with T2DM. We then examined the
152 correlation of $K_{ITT(iv)}$ with the HOMA-IR value and $K_{ITT(sc)}$ using Pearson's correlation coefficient
153 analysis. The intraclass correlation coefficient (ICC) was also used to assess the relationship between
154 $K_{ITT(iv)}$ and $K_{ITT(sc)}$. We further analyzed the association of $K_{ITT(iv)}$ with VFA and other parameters
155 related to obesity and insulin resistance using a Pearson's correlation coefficient analysis. In addition, the
156 association of $K_{ITT(iv)}$ and the HOMA-IR value with the daily insulin dose required for glycemic control
157 was evaluated in patients with diabetes, using Pearson's correlation coefficient analysis. The frequency of
158 adverse events was analyzed using the McNemar test. All analyses were performed using JMP (SAS
159 institute, Cary, NC, USA).

160 Written informed consent was obtained from all individuals prior to participation in the study.
161 This study was approved by the ethics committee of the Hokkaido University Hospital (date of approval
162 25 October 2016; approval no. 016-0014) and registered in the University Hospital Medical Information
163 Network (UMIN000024453).
164

165 **Results**

166 The clinical characteristics of the participants are summarized in Table 1. Among the 17
167 patients with T2DM, eight (47.1%) were treated with antihypertensive agents, eight (47.1%) with
168 hyperlipidemic agents, two (11.8%) with sulfonylurea, five (29.4%) with insulin, six (35.3%) with
169 metformin, five (29.4%) with dipeptidyl peptidase 4 inhibitors, and two (11.8%) with sodium glucose
170 cotransporter 2 inhibitors.
171

172 **Table 1. Characteristics of the study participants**

	Healthy controls	Patients with type 2 diabetes mellitus	p values
n (men/women)	7 (4/3)	17 (14/3)	

Age (years)	39.3±13.3	62.2±23.0	<0.05
Body weight (kg)	62.7±18.3	68.5±19.1	0.19
Body mass index (kg/m ²)	22.3±4.8	24.9±5.2	<0.05
Waist circumference (cm)	78.4±12.7	93.6±16.4	<0.05
Waist-to-hip ratio	0.8±0.1	1.0±0.1	<0.05
Visceral fat area (cm ²)	55.5±33.9	92.8±63.0	<0.05
Fasting plasma glucose (mg/dL)	94.0±15.2	172.1±93.6	<0.05
Immunoreactive insulin (μIU/mL)	4.7±3.7	4.5±4.3	0.67
Fasting C-peptide radioactivity (ng/mL)	1.2±0.6	1.7±1.0	<0.05
HOMA-IR	1.1±0.9 ^a	1.9±2.3 ^b	0.09
K _{ITT(iv)} (%)	4.5±1.8	2.5±2.1	<0.05
K _{ITT(sc)} (%)	0.3±0.3	0.5±0.5	<0.05
Adiponectin (μg/mL)	10.9±10.1	5.9±4.0	<0.05
Leptin (ng/mL)	8.1±6.7	10.0±8.6	0.31
Adiponectin/Leptin	1.5±1.2	0.7±1.1	<0.05
Tumor necrosis factor-α (pg/mL)	0.6±0.9	1.2±0.5	<0.05
Branched chain amino acid/total amino acid	0.15±0.04	0.16±0.03	<0.05

^a n=6

^b n=11

HOMA-IR, homeostatic model assessment for insulin resistance; K_{ITT(iv)}, K index of the intravenous insulin tolerance test; K_{ITT(sc)} calculated from the linear slope of the curve of plasma glucose concentrations at the 30–120-min timepoints using the Lundbaek equation

173

174 The mean K_{ITT(iv)} was significantly higher in the controls than in the patients (4.5%±1.8% vs.
175 2.5%±2.1%). Conversely, the mean HOMA-IR value was lower in the controls than in the patients
176 (1.1±0.9 vs. 1.9±2.3). However, the mean K_{ITT(sc)} did not differ significantly between the controls and
177 the patients (0.3%±0.3% vs. 0.5%±0.5%).

178 In all participants, there was a significant correlation between K_{ITT(iv)} and the HOMA-IR value
179 (r=-0.601, p<0.05; Fig 2a); conversely, there was no significant correlation between K_{ITT(iv)} and K_{ITT(sc)}
180 (ICC=0, p=0.62; Fig 2b). As shown in Fig 3, K_{ITT(iv)} was negatively correlated with FPG (r=-0.673,
181 p<0.05), CPR (r=-0.489, p<0.05), TNF-α (r=-0.648, p<0.05), BCAA/total AA (r=-0.64, p<0.05), and
182 VFA (BIM; r=-0.444, p<0.05); it was positively correlated with the adiponectin concentration (r=0.487,
183 p<0.05).

184

185 **Fig 2. Relationship of K_{ITT(iv)} with the HOMA-IR value and K_{ITT(sc)}.**

186 (a) $K_{ITT}(iv)$ was significantly correlated with the HOMA-IR value ($r=-0.601$, $p<0.05$). (b) $K_{ITT}(iv)$ was not
187 correlated with $K_{ITT}(sc)$.

188 $K_{ITT}(iv)$, K index of the intravenous insulin tolerance test; HOMA-IR, homeostasis model assessment
189 for insulin resistance; $K_{ITT}(sc)$, K index of the subcutaneous insulin tolerance test

190

191 **Fig 3. Relationship of $K_{ITT}(iv)$ with other parameters.**

192 (a) $K_{ITT}(iv)$ was negatively correlated with the visceral fat area ($r=-0.444$, $p<0.05$), (b)fasting plasma
193 glucose ($r=-0.673$, $p<0.05$), (c)fasting serum C-peptide ($r=-0.489$, $p<0.05$), (e)TNF- α ($r=-0.648$,
194 $p<0.05$), and (f)BCAA/total AA ($r=-0.64$, $p<0.05$). (d)It was positively correlated with the adiponectin
195 level ($r=0.487$, $p<0.05$).

196 $K_{ITT}(iv)$, K index of the intravenous insulin tolerance test; TNF- α , tumor necrosis factor- α ; BCAA,
197 branched-chain amino acid; AA, amino acid

198

199 In the 17 patients with T2DM, the mean total insulin dose used for glycemic control was
200 36.2 ± 28.1 U/day, and the mean total insulin dose/body weight was 0.5 ± 0.4 U/kg. The mean total insulin
201 dose/body weight was negatively correlated with $K_{ITT}(iv)$ ($r=-0.550$, $p<0.05$), and it was calculated using
202 the following regression equation (Fig 4a): total insulin dose/kg = $0.78-0.10\times K_{ITT}(iv)$. The mean total
203 insulin dose/body weight was positively correlated with the HOMA-IR value ($r=0.806$, $p<0.05$), and it
204 was calculated using the following regression equation (Fig 4b): total insulin dose/kg = $0.23+0.15\times$
205 HOMA-IR value.

206

207 **Fig 4. Relationship of $K_{ITT}(iv)$ and the HOMA-IR value with the mean total insulin dose/kg.**

208 (a) $K_{ITT}(iv)$ was significantly correlated with the mean total insulin dose per body weight ($r=-0.550$,
209 $p<0.05$); this was estimated using with the following regression equation: total insulin dose/kg = $0.78-$
210 $0.10\times K_{ITT}(iv)$. (b)The HOMA-IR value was also significantly correlated with the mean total insulin dose
211 per body weight ($r=0.806$, $p<0.05$); this was estimated using with the following regression equation: total
212 insulin dose/kg = $0.23+0.15\times$ HOMA-IR.

213 $K_{ITT}(iv)$, K index of the intravenous insulin tolerance test; HOMA-IR, homeostasis model assessment for
214 insulin resistance

215

216 Seven and two adverse events occurred in participants undergoing the SITT and ITTsc,
217 respectively. All adverse events were hypoglycemia. No significant difference was observed in the
218 frequency of adverse events between participants undergoing the SITT and the ITTsc.

219

220 **Discussion**

221 In the present study, we prospectively studied seven healthy controls and 14 patients with
222 T2DM and evaluated their insulin resistance using $K_{ITT}(iv)$. The following four main results were
223 obtained: 1) the $K_{ITT}(iv)$ of patients with T2DM was $2.5\% \pm 2.1\%$, which was significantly lower than that
224 of the controls ($4.5\% \pm 1.8\%$); 2) $K_{ITT}(iv)$ was significantly correlated with the HOMA-IR value but not
225 with $K_{ITT}(sc)$; 3) $K_{ITT}(iv)$ was significantly correlated with VFA and the serum glucose, CPR, TNF- α ,
226 BCAA/total AA, and adiponectin concentrations; and 4) the total insulin dose required for glycemic
227 control was correlated with $K_{ITT}(iv)$ and the HOMA-IR value, and it was estimated using an equation in
228 patients with T2DM.

229 HOMA-IR values are widely used as indices of insulin resistance [13, 14]; however, their
230 reliability decreases when the insulin secretion is reduced and hyperglycemia occurs [4]. In the present
231 study, there was a significant correlation between the HOMA-IR value and $K_{ITT}(iv)$, suggesting its
232 applicability as an index of insulin resistance even in a cohort including healthy volunteers and patients
233 with poorly controlled T2DM. The significant correlation between the HOMA-IR value and $K_{ITT}(iv)$ may
234 be attributed to the fact that the FPG level was not very high and the decrease in insulin secretion was
235 only mild in our patients with T2DM. A previous study revealed that the HOMA-IR value is a useful
236 index for determining insulin resistance at an FPG range of 80–170 mg/dL in obese Japanese patients
237 with T2DM [4]. In fact, in this study, the mean FPG level of patients with T2DM was approximately 170
238 mg/L (Table 1), and the correlation observed between CPR and K_{ITT} supports the fact that the HOMA-IR
239 value can be used as an effective index in this group (Fig 2b). In addition, the association between the two
240 indices was observed even in the controls, which might have led to the significant correlation between the
241 two indices in all study participants. Although the HOMA-IR data in this study were exclusive of patients
242 on insulin therapies for diabetes, Okita et al. [10] reported that K_{ITT} in such patients can be a useful
243 indicator of insulin resistance using the euglycemic clamp test.

244 We expected that $K_{ITT}(sc)$ would be correlated with $K_{ITT}(iv)$ because the pattern of glucose
245 level changes, unlike the rate of action, in an individual may be similar between intravenous and
246 subcutaneous routes of insulin administration. In addition, the accuracy of finger-prick tests for blood
247 glucose measurement has substantially improved [15]. However, contrary to our expectations, there was
248 no significant correlation between $K_{ITT}(iv)$ and $K_{ITT}(sc)$ (ICC=0). A possible explanation for this
249 dissociation may be the instability of the insulin absorption rate due to differences in the skinfold
250 thickness and subcutaneous blood flow [16, 17]. Exercise, smoking, and body position are also reported
251 to affect insulin absorption [16, 17]. However, in this study, all patients were resting, had stopped
252 smoking, and were sitting; thus, we considered these factors to have no effect. Previous studies [18–21]
253 have compared glycemic control between intravenous and subcutaneous routes of insulin administration
254 mainly in intensive care units; however, to our knowledge, there are no crossover studies comparing the
255 two routes in the same individuals.

256 In this study, $K_{ITT}(iv)$ was correlated with various clinical parameters associated with obesity

257 and insulin resistance, including VFA, adiponectin, tumor necrosis factor alpha (TNF- α), and branched
258 chain amino acids (BCAA)/total AA. Obesity and visceral fat are closely associated with insulin
259 resistance; thus, the significant correlation between $K_{ITT}(iv)$ and the VFA was considered reasonable
260 [10, 22]. Low adiponectin levels were also associated with an increased risk of insulin resistance [23], and
261 TNF- α is a strong inhibitor of adiponectin promoter activity [24]. In non-obese, non-diabetic individuals,
262 no significant correlation was observed between adipose tissue TNF- α mRNA content and $K_{ITT}(iv)$ [25].
263 However, when including patients with T2DM and a tendency for obesity, positive and negative
264 correlations of $K_{ITT}(iv)$ with adiponectin and TNF- α , respectively, were observed in prior investigations
265 similar to in our study[10]. In addition, in our study, $K_{ITT}(iv)$ was negatively associated with BCAAs/total
266 AAs. This corroborates the findings of prior studies that revealed a significant association between insulin
267 resistance and BCAAs [26, 27]. In fact, BCAAs were reported to accumulate under conditions of insulin
268 resistance [28]; furthermore, a positive association of insulin resistance with valine, one of the three
269 BCAAs, has been reported in Japanese healthy individuals [29].

270 To the best of our knowledge, this is the first report on a regression equation for calculating the
271 insulin dose required for glycemic control based on $K_{ITT}(iv)$. It is useful for adjusting the insulin dose and
272 avoiding hypoglycemic events. Notably, the correlation coefficient was better for the HOMA-IR value
273 ($r=0.806$) than for $K_{ITT}(iv)$ ($r=-0.550$), suggesting that the HOMA-IR value is an easily applicable
274 parameter that helps estimate the insulin dose required for glycemic control.

275 This study had several limitations. First, the sample size was small and the study was
276 conducted at a single center. Second, there was significant heterogeneity among participants in terms of
277 the age, sex, comorbidities, and treatment regimens (in patients with T2DM). The first and second
278 limitations precluded robust statistical analyses. Finally, we did not verify the reproducibility and
279 reliability of the equations for calculating the total insulin dose using the HOMA-IR value and $K_{ITT}(iv)$.

280 In conclusion, $K_{ITT}(iv)$ was associated with the HOMA-IR value and insulin resistance-related
281 parameters (such as VFA, adiponectin, and BCAAs). $K_{ITT}(iv)$ is an index of insulin resistance that can be
282 applied in clinical practice; along with HOMA-IR, it may be useful for efficiently adjusting insulin doses.
283

284 **Acknowledgements**

285 None

286

287 **Data availability**

288 The data presented in this manuscript are accessible and can be provided on reasonable request to the
289 corresponding author.

290

292 **References**


- 293 1. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion
294 responsible for NIDDM. *Diabetes*. 1988;37: 667-687.
- 295 2. Godsland IF, Stevenson JC. Insulin resistance: syndrome or tendency? *Lancet*. 1995;346:
296 100-103.
- 297 3. Bonora E, Moghetti P, Zaccanaro C, Cigolini M, Querena M, Cacciatori V, et al. Estimates
298 of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and
299 hyperglycemic glucose clamp studies. *J Clin Endocrinol Metab*. 1989;68: 374-378.
- 300 4. Ono T, Shiga N, Taneda Y, Umemura S. The fasting-plasma glucose range in which insulin
301 resistance measured by homeostasis model assessment correlates with euglycemic clamping.
302 *J Japan Diab Soc*. 1999;42: 1005-1011.
- 303 5. Young RP, Critchley JA, Anderson PJ, Lau MS, Lee KK, Chan JC. The short insulin
304 tolerance test: feasibility study using venous sampling. *Diabet Med*. 1996;13: 429-433.
- 305 6. Hirst S, Phillips DI, Vines SK, Clark PM, Hales CN. Reproducibility of the short insulin
306 tolerance test. *Diabet Med*. 1993;10: 839-1842.
- 307 7. Akinmokun A, Selby PL, Ramaiya K, Alberti KG. The short insulin tolerance test for
308 determination of insulin sensitivity: a comparison with the euglycaemic clamp. *Diabet Med*.
309 1992;9: 432-427.
- 310 8. Chen CC, Wang TY, Hsu SY, Chen RH, Chang CT, Chen SJ. Is the short insulin tolerance
311 test safe and reproducible? *Diabet Med*. 1998;15: 924-927.
- 312 9. Graci S, Baratta R, Degano C, Luppá A, Vigneri R, Frittitta L, et al. The intravenous insulin
313 tolerance test is an accurate method for screening a general population for insulin resistance
314 and related abnormalities. *J Endocrinol Invest*. 1999;22: 472-475.
- 315 10. Okita K, Iwahashi H, Kozawa J, Okauchi Y, Funahashi T, Imagawa A, et al. Usefulness of
316 the insulin tolerance test in patients with type 2 diabetes receiving insulin therapy. *J*
317 *Diabetes Investig*. 2014;5: 305-312.
- 318 11. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes*
319 *Care*. 2010;33: S62-S69.
- 320 12. Lundbaek K. Intravenous glucose tolerance as a tool in definition and diagnosis of diabetes
321 mellitus. *Br Med J*. 1962;1: 1507-1513.
- 322 13. González-González JG, Violante-Cumpa JR, Zambrano-Lucio M, Burciaga-Jimenez E,
323 Castillo-Morales PL, Garcia-Campa M, et al. HOMA-IR as a predictor of health outcomes
324 in patients with metabolic risk factors: a systematic review and meta-analysis. *High Blood*
325 *Press Cardiovasc Prev*. 2022;29: 547-564.
- 326 14. Tahapary DL, Pratisthita LB, Fitri NA, Marcella C, Wafa S, Kurniawan F, et al. Challenges

- 327 in the diagnosis of insulin resistance: focusing on the role of HOMA-IR and
328 Tryglyceride/glucose index. *Diabetes Metab Syndr.* 2022;16: 102581.
- 329 15. King F, Ahn D, Hsiao V, Porco T, Klonoff DC. A review of blood glucose monitor
330 accuracy. *Diabetes Technol Ther.* 2018;20: 843-856.
- 331 16. Hildebrandt P. Subcutaneous absorption of insulin in insulin-dependent diabetic patients.
332 Influence of species, physico-chemical properties of insulin and physiological factors. *Dan*
333 *Med Bull.* 1991;38: 337-346.
- 334 17. Gradel AKJ, Porsgaard T, Lykkesfeldt J, Seested T, Gram-Nielsen S, Kristensen NR, et al.
335 Factors affecting the absorption of subcutaneously administered insulin: effect on
336 variability. *J Diabetes Res.* 2018;2018: 1205121.
- 337 18. Neff K, Donegan D, MacMahon J, O'Hanlon C, Keane N, Agha A, et al. Management of
338 parenteral nutrition associated hyperglycaemia: a comparison of subcutaneous and
339 intravenous insulin regimen. *Ir Med J.* 2014;107: 141-143.
- 340 19. Bodur HA, Saygili F, Saygili S, Doganay LH, Yesil S. Continuous infusion of subcutaneous
341 compared to intravenous insulin for tight glycaemic control in medical intensive care unit
342 patients. *Anaesth Intensive Care.* 2008;36: 520-527.
- 343 20. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion
344 reduces the incidence of deep sternal wound infection in diabetic patients after cardiac
345 surgical procedures. *Ann Thorac Surg.* 1999;67: 352-360.
- 346 21. Pezzarossa A, Taddei F, Cimicchi MC, Rossini E, Contini S, Bonora E, et al. Perioperative
347 management of diabetic subjects. Subcutaneous versus intravenous insulin administration
348 during glucose-potassium infusion. *Diabetes Care.* 1988;11: 52-58.
- 349 22. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and
350 type 2 diabetes. *Nature.* 2006;444: 840-846.
- 351 23. Moon HU, Ha KH, Han SJ, Kim HJ, Kim DJ. The association of adiponectin and visceral
352 fat with insulin resistance and β -cell dysfunction. *J Korean Med Sci.* 2018;34: e7.
- 353 24. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al.
354 PPAR γ ligands increase expression and plasma concentrations of adiponectin, an
355 adipose-derived protein. *Diabetes.* 2001;50: 2094-2099.
- 356 25. Frittitta L, Youngren JF, Sbraccia P, D'Adamo M, Buongiorno A, Vigneri R, et al. Increased
357 adipose tissue PC-1 protein content, but not tumour necrosis factor- α gene expression, is
358 associated with a reduction of both whole body insulin sensitivity and insulin receptor
359 tyrosine-kinase activity. *Diabetologia.* 1997;40: 282-289.
- 360 26. Allam-Ndoul B, Guénard F, Garneau V, Barbier O, Pérusse L, Vohl M. Associations
361 between branched chain amino acid levels, obesity and cardiometabolic complications.
362 *Integr Obesity Diabetes.* 2015;1: 157-162.

- 363 27. Elshorbagy A, Jernerén F, Basta M, Basta C, Turner C, Khaled M, et al. Amino acid
364 changes during transition to a vegan diet supplemented with fish in healthy humans. *Eur J*
365 *Nutr.* 2017;56: 1953-1962.
- 366 28. Lynch CJ, Adams SH. Branched-chain amino acids in metabolic signalling and insulin
367 resistance. *Nat Rev Endocrinol.* 2014;10: 723-736.
- 368 29. Takashina C, Tsujino I, Watanabe T, Sakaue S, Ikeda D, Yamada A, et al. Associations
369 among the plasma amino acid profile, obesity, and glucose metabolism in Japanese adults
370 with normal glucose tolerance. *Nutr Metab (Lond).* 2016;13: 5




CONSORT 2010 Flow Diagram




Figure

a. KITT(iv) vs HOMA-IR




b. KITT(iv) vs KITT(sc)




Figure


a. Visceral fat area




b. Fasting plasma glucose




c. Fasting C-peptide




d. Adiponectin



e. TNF-α




f. BCAA/total AA




Figure

a. KITT(iv) vs mean total insulin dose/kg



b. HOMA-IR vs mean total insulin dose/kg



Figure